Skip to main content

Table 3 Total body weight gain percentage by CYP phenotype in participants prescribed with citalopram, paroxetine, fluoxetine, and sertraline

From: Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study

 

Poor/intermediate metabolizer

Normal metabolizer

Rapid/ultra-rapid metabolizer

p- value

CYP2C19

Citalopram

  TBWG 6 months, %

2.6 (95% CI 1.3 – 4.1)

0.4 (95% CI -0.5 – 1.3)

-0.1 (95% CI -1.5 – 1.1)

0.001

Sertraline

 TBWG 6 months, %

0.9 (95% CI -0.09 – 2.1)

0.4 (95% CI -0.6 – 1.5)

1.7 (95% CI 0.7 – 2.9)

0.13

CYP2D6

Paroxetine

  TBWG 6 months, %

0.7 (95% CI -0.1 – 1.5)

1.6 (95% CI 0.2 – 2.9)

0.7 (95% CI -4.8 – 6.1)

0.50

Sertraline

 TBWG 6 months, %

1.1 (95% CI 0.4 – 1.9)

0.8 (95% CI -0.3 – 1.8)

0.9 (95% CI -9.0 – 10.9)

0.98

Fluoxetine

 TBWG 6 months, %

0 (95% CI -0.7 – 0.7)

0.2 (95% CI -1.2 – 1.5)

1.3 (95% CI -3 – 3)

0.84

CYP2C9

Fluoxetine

  TBWG 6 months, %

0.5 (95% CI -0.5 – 1.6)

-0.1 (95% CI -1.1 – 0.6)

 

0.33

  1. Continuous data are summarized as mean and 95% confidence interval (CI)
  2. Abbreviations used: TBWG Total Body Weight Gain
  3. p-value: calculated with ANCOVA with metabolizer status and BMI as covariates